It got a different effect on different monkeys. "It's going to be a single dose vaccine".
Business Secretary Alok Sharma has said the clinical trial for a Covid-19 vaccine at the University of Oxford is progressing well.
And injecting the vaccine, which contains a weakened version of the virus, did not cause Covid-19 to form in the monkeys. The results from the project are said to be promising but no guarantees can yet be given that the vaccine will works on humans. The first signals on whether and how well it works could come as early as July or August.
On Saturday, Chinese health official, Zhang Wenhong said a successful vaccine against the coronavirus can be administered to humans as early as March in 2021.
He said: "Last month I announced a new vaccine task force to co-ordinate the efforts of Government, academia and industry in the critical mission to find a vaccine". However, it is still not 100% certain that the results apply to humans.
Nearly 4.5 million people have been reported to be infected by the novel coronavirus globally and more than 301,000 have died, according to a Reuters tally.
Tesla's latest invention: Secret low-priced batteries that last a million miles
Earlier this year, it said only that it planned to "drive battery cell costs below $100/kWh" without specifying a timetable. Dahn and his team have been working on the project with Tesla since 2016, but their relationship extends back to 2012.
When asked why it isn't enough to show that a vaccine elicits an antibody response - and why more testing is needed, Dr. Kathryn Edwards who directs vaccine research at Vanderbilt University said, "we need to know that it protects the animal or the human from the infection".
The ChAdOx vaccine, a sort often known as a recombinant viral vector vaccine, makes use of a weakened model of the common-cold virus spiked with proteins from the novel coronavirus to generate a response from the physique's immune system.
Now this vaccine is being tested on humans.
In an interview with Bloomberg News, Hudson said that "the USA government has the right to the largest pre-order because it's invested in taking the risk", referring the Trump administration has expanded a vaccine partnership with the company and has expected "that if we have helped you manufacture the doses at risk, we expect to get the doses first". Those embrace India's Serum Institute in addition to websites in Europe and China.
"Ideally we'd want seven or eight billion doses the day after licensure, so we can vaccinate the whole world", said Walter Orenstein, associate director of Emory University's vaccine center in Atlanta. Under the contract, if the vaccine is successful, AstraZeneca will work to make 30m doses available to the United Kingdom by September, with a further 70m earmarked for the USA and the rest of the world. "And one of the reasons that we chose Astrazeneca was because they shared that ambition and they were convincing that they could provide supply and large scale".